News
PDSB
4.225
+3.30%
0.135
Weekly Report: what happened at PDSB last week (0701-0705)?
Weekly Report · 07/08 10:07
Weekly Report: what happened at PDSB last week (0624-0628)?
Weekly Report · 07/01 10:07
Weekly Report: what happened at PDSB last week (0617-0621)?
Weekly Report · 06/24 10:11
Weekly Report: what happened at PDSB last week (0610-0614)?
Weekly Report · 06/17 10:06
PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 06/12 17:43
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Benzinga · 06/12 17:33
PDS Biotechnology Price Target Cut to $9.00/Share From $11.00 by B. Riley Securities
Dow Jones · 06/12 14:25
PDS Biotechnology Is Maintained at Buy by B. Riley Securities
Dow Jones · 06/12 14:25
B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $9
Benzinga · 06/12 14:15
H.C. Wainwright Keeps Their Buy Rating on PDS Biotechnology (PDSB)
TipRanks · 06/12 14:06
PDS BIOTECH PROVIDES DATA UPDATE FROM ONGOING VERSATILE-002 PHASE 2 CLINICAL TRIAL IN HEAD AND NECK CANCER
Reuters · 06/12 12:00
Weekly Report: what happened at PDSB last week (0603-0607)?
Weekly Report · 06/10 10:08
Weekly Report: what happened at PDSB last week (0527-0531)?
Weekly Report · 06/03 10:09
Weekly Report: what happened at PDSB last week (0520-0524)?
Weekly Report · 05/27 10:11
Weekly Report: what happened at PDSB last week (0513-0517)?
Weekly Report · 05/20 10:08
'PDS Biotech's Survival Benefit Is Absurdly Overstated' - By Adam Feuerstein/ STAT News
Adam's Biotech Scorecard: PDS Biotech and its experimental drug for head and neck cancer. PDS is a biotech cult stock. Adam is in San Francisco for the STAT Breakthrough Summit. He'll be chatting with Cytokinetics CEO Robert Blum later today.
Benzinga · 05/16 15:03
Financial Report Articles: Quarterly Report for the Period Ended March 31, 2024
Press release · 05/15 22:25
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024
PDS Biotechnology reported earnings per share of -30 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -37 cents. PDS Biotech reported results for the fourth quarter of 2016.
Investorplace · 05/15 16:52
PDS Biotechnology Corp reports results for the quarter ended in March - Earnings Summary
PDS Biotechnology Corp reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 30 cents per share. The mean expectation of six analysts was for a loss of 37 cents. Reported revenue was zero; analysts expected zero. The average analyst rating on the shares is "buy"
Reuters · 05/15 14:51
PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 05/15 14:34
More
Webull provides a variety of real-time PDSB stock news. You can receive the latest news about Pds Biotechnology Corporation through multiple platforms. This information may help you make smarter investment decisions.
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.